Dive Insight:
While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion.
Amgen's seen the sequencing...
Clovis' Rubraca (rucaparib) was given an accelerated approval in December 2016 for advanced and pretreated ovarian cancer. However, the Colorado-based biotech still lags behind...
While BioMarin and Spark remain out in front, Sangamo's data appear strong enough to warrant consideration of the biotech's therapy in the discussion of...
While Bristol-Myers executives successfully beat back Starboard and Wellington's efforts to derail the deal, the questions raised by that opposition remain.
By buying Celgene, Bristol-Myers...
Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's.
Wall Street analysts,...
The U.S. opioid crisis breathed new life into clinical development of the nerve-growth factor (NGF) inhibitors tanezumab and fasinumab. The drug class had been...
SAN FRANCISCO — Developing new medicines isn't a resource-efficient endeavor.
Estimates vary, but most molecules selected to begin clinical development won't end up on pharmacy...
Denali started 2018 with one research agreement with Takeda and is now ending the year with another big pharma collaboration.
The Takeda deal, announced in...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...
